Login

Recent searches

No recent searches

Search options

Only available when logged in.
social.coop is one of the many independent Mastodon servers you can use to participate in the fediverse.
A Fediverse instance for people interested in cooperative and collective projects. If you are interested in joining our community, please apply at https://join.social.coop/registration-form.html.

Administered by:

Server stats:

489
active users

social.coop: AboutStatusProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.4

#covid19

98 posts73 participants7 posts today
Public *
Anti. 🐘

· People with recent COVID-19 at higher risk for other viral and bacterial infections
· A 15-day course of #Paxlovid did not “significantly improve health outcomes in participants with #LongCOVID
· 2. study showed that Paxlovid taken within 5 days of infection with COVID-19 did help with the acute phase of COVID-19 in children
· Rapamycin, a drug used for organ transplants, may help alleviate symptoms of myalgic encephalomyelitis #MECFS

thesicktimes.org/2025/04/08/re

The Sick Times - Chronicling the Long Covid crisis · Research updates, April 8 - The Sick TimesPeople who recently had COVID-19 are at higher risk for other viral and bacterial infections, according to a paper published in The Lancet Infectious Diseases. The researchers used Veterans Affairs electronic health records from over 800,000 people, and compared infection history between those who had a positive COVID-19 test and those who did not. Those who tested positive had higher rates of bacterial and viral infections, including Epstein-Barr virus and seasonal respiratory viruses, in the year following their COVID-19 diagnosis.
#ResearchUpdates#COVID19
Continued thread
Public
☮ ♥ ♬ 🧑‍💻

Day eleven cont: 🗣️🎙️🙊

The #LNP have a candidate problem cont…

“A #Liberal #National candidate (#JeremyNeal) in a must-win #Queensland seat has apologised after #SocialMedia posts airing controversial views about #China, #Covid19 restrictions and “#feminists” who helped “kick out” Donald Trump 🎃in 2020 resurfaced.”

So you chastise Political candidates who have an opinion and tell their truth OR chastise them because they are not tactful? (ie: don’t disclose what they think, lie etc.)

#AusPol / #Politics / #tact / #Machiavellian <theguardian.com/australia-news>

The Guardian · LNP candidate in critical Queensland seat apologises after controversial posts on China and ‘feminists’ resurfaceBy Dan Jervis-Bardy
Continued thread
Public
Tom Kindlon

3/
Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with #longCOVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial

Image is from latest Science for ME weekly update

thelancet.com/journals/laninf/

@longcovid
#PASC #PwLC #postcovid #postcovid19 #LC #Covidlonghaulers #PostCovidSyndrome #longhaulers #COVIDBrain #NeuroPASC
@covid19 #Coronavirus
#COVID19 #COVID #COVID_19 #COVIDー19 #SARSCoV2 @novid@chirp.social #novid @novid@a.gup.pe #CovidIsNotOver
@auscovid19

The Lancet Infectious Diseases Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial — Mitsuaki Sawano et al. "Nirmatrelvir–ritonavir administered for 15 days did not significantly improve health outcomes in participants with long COVID compared with placebo–ritonavir at day 28."
Public
fasel

versuche die ganze Zeit dahinter zu kommen, welchen genialen Masterplan die #US Regierung wohl verfolgt.

Jetzt fällt mir ein, dass es wahrscheinlich einfach die Politik von Leuten ist, die es für clever hielten, sich Chlorreiniger statt Impfe gegen #covid19 zu spritzen

Public
Science-Presse

S’il ne fait plus de doute que la #désinformation en santé peut accroître le risque qu’une personne soit malade ou hospitalisée, une difficulté reste de calculer ce risque. Une équipe italo-américaine propose une série de simulations qui, en prenant la #Covid19 comme modèle, concluent que, dans le scénario du pire, 47 millions d’Américains de plus, ou 14% de la population, seraient infectés.

sciencepresse.qc.ca/actualite/

Agence Science-PresseMesurer l’impact de la désinformation sur la santéS’il ne fait plus de doute que la désinformation en santé peut accroître le risque qu’une personne soit malade ou hospitalisée, une difficulté reste de calculer ce risque. Une équipe italo-américaine propose une série de simulations qui concluent que, dans le scénario du pire, 47 millions d’Américains de plus auraient été infectés pendant la COVID.
Public
Tom Kindlon

"Does Paxlovid reduce #longCOVID symptoms? Yale-led trial finds out"
eurekalert.org/news-releases/1

"PAX LC team pioneered a novel, decentralized design that brought the trial into 100 participants’ homes...first fully decentralized phase 2 trial of its scale"

Method could be useful in #MEcfs

@longcovid
#PASC #PwLC #postcovid #postcovid19 #LC #Covidlonghaulers #PostCovidSyndrome #longhaulers #COVIDBrain #NeuroPASC
@covid19 #Coronavirus
#COVID19 #COVID #COVID_19 #COVIDー19 #SARSCoV2 @mecfs

News Release 7-Apr-2025 Does Paxlovid reduce long COVID symptoms? Yale-led trial finds out Peer-Reviewed Publication Yale University Antiviral medications nirmatrelvir/ritonavir (Paxlovid) were not effective in relieving long COVID symptoms, according to a new study published in The Lancet Infectious Diseases on April 3. The findings came from the Yale Paxlovid for Long COVID (PAX LC) Trial, led by principal investigator Dr. Harlan Krumholz, Harold H. Hines, Jr. Professor of Medicine (Cardiology), and Akiko Iwasaki, Sterling Professor of Immunobiology. The phase 2 investigational new drug clinical trial tested whether a 15-day course of Paxlovid, an FDA-approved antiviral for acute COVID-19, could also help long COVID patients. The PAX LC team pioneered a novel, decentralized design that brought the trial into 100 participants’ homes around the nation. It’s the first fully decentralized phase 2 trial of its scale, the researchers say.
Public
cremevax👩🏻‍💻🏳️‍🌈​🇨🇦🇺🇦

Derek Lowe has a blog post about some very early stage work on an antiviral treatment that targets Sars-CoV-2, plus other coronaviruses: science.org/content/blog-post/.

In the shorter term, Pfizer has started Phase 3 trials for a next-gen Paxlovid. There are a fair number of patients for whom Paxlovid isn't suitable owing to medication interactions; this version has been designed to reduce those limitations. The study sites are in the US and some are recruiting now. The clinical trials docs are here: clinicaltrials.gov/study/NCT06. #covid #COVID19

H/t to @bert_hubert for the pointer to the Derek Lowe post.

Public
WHN

Aren't you tired of being sick and tired?

COVID-19 isn't just another cold. It can cause lasting harm even without symptoms. We have the power to break this cycle. Wearing a high-quality mask in public drastically reduces infections, protecting you and your community.

Together, we can stop the spread. Mask up, stay safe, and reclaim your health.

#longcovidrecovery#covid#MaskUp
ExploreLive feeds
About